

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Rainer BISCHOFF et al.

Application No.: Unassigned  
(Continuation of Serial No.  
09/171,845)

Filed: December 18, 2001

For: NOVEL LIPID COMPOUNDS AND  
COMPOSITIONS CONTAINING SAME  
USED FOR THE TRANSFER OF AT  
LEAST AN ACTIVE SUBSTANCE, IN  
PARTICULAR A POLYNUCLEOTIDE,  
INTO A TARGET CELL AND  
THERAPEUTIC USE

Group Art Unit: Unassigned

Examiner: Unassigned

#4/R.T.  
5/4  
I.D.S.

INFORMATION DISCLOSURE STATEMENT  
TRANSMITTAL LETTER

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.


- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge \$\_\_\_\_\_ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of \$\_\_\_\_\_ is enclosed for the fee due.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

By:   
Dawn M. Gardner  
Registration No. 44,118

Date: December 19, 2001

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of )  
 )  
Rainer BISCHOFF et al. )  
 )  
Application No.: Unassigned ) Group Art Unit: Unassigned  
 (Continuation of Serial )  
 No. 09/171/845 )  
 )  
Filed: December 18, 2001 ) Examiner: Unassigned  
 )  
For: NOVEL LIPID COMPOUNDS AND )  
 COMPOSITIONS CONTAINING )  
 SAME USED FOR THE TRANSFER )  
 OF AT LEAST AN ACTIVE )  
 SUBSTANCE, IN PARTICULAR A )  
 POLYNUCLEOTIDE, INTO A )  
 TARGET CELL AND THERAPEUTIC )  
 USE )

**INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:


In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited on the attached PTO Form 1449 were submitted or cited in parent Application Serial No. 09/171,845, Thus, these documents are not enclosed herewith.

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b).

To assist the Examiner, the above-cited documents are listed on the attached forms PTO-1449. It is respectfully requested that an Examiner initialled copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By:   
Dawn M. Gardner  
Registration No. 44,118

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

Date: December 19, 2001

